BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2016

Dec 21, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2016-12-19

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-19	Common Stock	M	3250	$3.78	Acquired	127437	Direct
2016-12-19	Common Stock	S	3250	$7.45	Disposed	124187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-19	Emp. Stock Option (Right to Buy)	$3.78	M	3250	Disposed	2021-07-01	Common Stock (3250)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016.